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Abstract
Crohn’s disease and ulcerative colitis are 
chronic relapsing gastrointestinal conditions 
characterised by an infl ux of infl ammatory cells 
to the affected gut mucosa. The mainstay of 
diagnosing and re-evaluating these conditions 
in clinical practice and research is by invasive 
serological, radiological, endoscopic and 
histological assessment. In clinical trials, disease 
activity is often evaluated using a combination 
of the above tests plus clinical indices such 
as the Crohn’s Disease Activity Index and 
Ulcerative Colitis Activity Index. These tools 
rely on subjective assessment of symptoms 
and so, often, do not correlate with mucosal 
infl ammation or mucosal healing, which may be 
the preferred therapeutic end point for long-term 
infl ammatory bowel disease (IBD) management. 
The faecal biomarkers calprotectin and lactoferrin 
are neutrophil derived proteins that are stable 
in faeces and can be detected by quantitative 
ELISA in small stool samples. Concentrations of 
both are raised in patients with gastrointestinal 
mucosal infl ammation. They provide a unique, 
inexpensive, non-invasive method of testing for 
active infl ammatory disease. They can be used 
to screen for IBD and as a surrogate marker of 
mucosal healing they are useful in monitoring 
the response to therapeutic intervention or 
surgery. They may also predict the clinical 
course of the disease. This clinical review aims 
to discuss the current evidence, limitations and 
potential future uses of these biomarkers in IBD.
Introduction
Crohn’s disease and ulcerative colitis 
(UC) are debilitating chronic relapsing 
inflammatory conditions for which there 
is no ideal treatment. There are a grow-
ing number of immunological treatments 
for both diseases, but these carry a risk of 
side effects and are costly. Consequently, 
patients must be carefully assessed and 
counselled about safe and appropriate use 
of these drugs.
Crohn’s disease is often the more clini-
cally challenging of the two conditions 
to manage. The changing phenotype of 
the condition often necessitates repeated 
radiological or endoscopic investigation 
to evaluate disease activity. These tests 
are invasive, often uncomfortable, pose 
risk of short term complications and long-
term side effects to the patient, are time 
consuming and costly.
Historically clinical practice and 
research trials have relied upon interpre-
tation of symptom activity to determine 
treatment success in inflammatory bowel 
disease (IBD). However, over the past 10 
years the concept of endoscopic ‘mucosal 
healing’ has emerged as a desirable end 
point of treatment. This suggests that the 
traditional methods of quantifying clini-
cal activity such as the Crohn’s Disease 
Activity Index (CDAI) and the Ulcerative 
Colitis Activity Index (UCAI), which pre-
dominantly rely on a subjective assess-
ment of symptom severity, may need to 
be revised or replaced by more objective 
measurements of mucosal disease activity.
What are calprotectin and lactoferrin?
Calprotectin is a protein complex of the 
S-100 family of calcium binding proteins. 
It is found in high concentrations within 
neutrophils comprising up to 60% of pro-
tein within the cytosol and is also present 
in monocytes and macrophages. It is 
released extracellularly during neutrophil 
activation or during cell death and also 
following endothelial adhesion of mono-
cytes. As a result it can be detected and 
quantified in fluids where inflammation 
is occurring for example serum, urine, 
cerebrospinal fluid and faeces.1 
Calprotectin has antimicrobial and anti-
proliferative effects that are mediated 
through zinc chelation, inhibiting met-
alloproteinases and inducing apoptosis. 
Interestingly in healthy newborns faecal 
calprotectin concentrations are signifi-
cantly elevated in the first month of life.1 
The rise appears to be most apparent in 
the first week after birth which may be 
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part of the body’s physiological defence mechanism 
against yeasts and fungi, allowing early development 
of gut homoeostasis.
Lactoferrin is one of the transferrin family of iron 
binding glycoproteins. It is contained within secondary 
neutrophil granulocytes but is also expressed in tear 
fluid, synovial fluid, breast milk and saliva.2 It too has 
an antimicrobial effect, principally through binding to 
and therefore starving micro-organisms of iron. It is 
active against bacteria, fungi and viruses. In viral infec-
tions it is thought to prevent entry of the virus into 
the host cell and is active against rotavirus, respiratory 
syncytial virus, herpes viruses as well as cytomegalovi-
rus and HIV.2
During intestinal inflammation both proteins are 
quickly released into the gut from where they can be 
quantified within faeces. Both resist proteolysis in the 
gut lumen and remain remarkably stable within faeces 
at room temperature for at least 7 days.3 4 This means 
that samples can be collected by the patient at home 
and sent by standard mail to the laboratory. When fro-
zen, both proteins remain stable long term allowing 
delayed analysis. Both can be measured commercially 
by quantitative ELISA a very small stool sample of 
0.05–0.1 g such that a collection of only a teaspoon 
sized sample or less is required from the patient.5 
The normal ranges are well defined as calprotectin 
<50 µg/g and lactoferrin <7.25 µg/g and have been 
demonstrated as raised in inflammatory, infective and 
neoplastic enteropathies.6–8
The concept of quantifying mucosal inflamma-
tion from white cell degradation products in faeces 
has existed for more than 30 years. Saverymuttu in 
the 1980s conducted a series of human experiments 
in patients with IBD infusing intravenous111Indium-
 labelled neutophilic granulocytes and measuring excre-
tion through 5 day collection of faeces. The results 
demonstrated highly significant correlation with 
CDAI, endoscopic severity, distribution and histologi-
cal activity.9–11 Although this method of investigation 
has been described as the ‘gold standard’ method of 
quantifying mucosal inflammation in IBD, it is cumber-
some, time consuming, expensive and exposes patients 
to ionising radiation. Therefore it is clearly not a test 
that can be used in routine practice, but these early 
experiments gave rise to the theory that perhaps there 
were other faecal biomarkers that could be more easily 
measured to non-invasively reflect mucosal inflamma-
tion. Subsequently in 1999, Roseth and colleagues pub-
lished the first comparative study of faecal calprotectin 
measurement with excretion of 111Indium-labelled 
neutrophilic granulocytes in a Norwegian popula-
tion of patients with Crohn’s disease, demonstrating 
that calprotectin measurement correlated very closely 
(p<0.0001, r=0.87).12 These findings were confirmed 
by a later United Kingdom (UK) study also demon-
strating good correlation between the two biomarkers 
(p<0.0001, r=0.70).13
The above studies highlighted faecal calprotectin 
measurement as a practical, safe and non-invasive 
method of quantifying intestinal inflammation, thus 
prompting an increasing number of studies in the fae-
cal biomarker field. Subsequently lactoferrin and cal-
protectin have been identified as the most clinically 
useful biomarkers. Both correlate strongly with one 
another, suggesting that measurement of either one is 
sufficient in clinical practice with little benefit derived 
from measurement of both biomarkers in individual 
patients.14 15
What are the uses of faecal biomarkers in IBD?
There are three broad areas within which faecal 
biomarkers in IBD have been studied: diagnostic exclu-
sion of active IBD, longitudinal monitoring of IBD and 
predicting the clinical course of IBD.
Diagnostic exclusion of active IBD
Abdominal pain and diarrhoea are common present-
ing symptoms to gastroenterology clinics. Without 
‘red flag’ or specific localising symptoms the diagnos-
tic spectrum is wide, from IBD and colonic cancer to 
functional diarrhoea and irritable bowel syndrome 
(IBS). Patients are often subjected to colonoscopy or 
radiological imaging. Consequently, faecal calprotec-
tin and lactoferrin have been studied with an aim of 
separating those patients with inflammatory organic 
pathology from those with non-inflammatory func-
tional pathology, thereby potentially avoiding the need 
for more invasive tests.
Faecal biomarkers are a measure of local gut inflam-
mation rather than systemic inflammation which is not 
always apparent in IBD. It is not surprising therefore, 
that calprotectin and lactoferrin have been demon-
strated as more effective in identifying disease activity 
than serum measurements of C-reactive peptide, leu-
cocyte count or erythrocyte sedimentation rate.14 16–18
It has been demonstrated that both calprotectin and 
lactoferrin levels are significantly higher in patients 
with active IBD than in healthy controls and those with 
IBS. In this setting the overall sensitivity and specifi-
city for calprotectin may be as high as 78–100% and 
76–100%, respectively, with a similar sensitivity and 
specificity for lactoferrin of 67–91% and 90–100%, 
respectively.6 7 13 16 19–29 A meta-analysis of facecal calpro-
tectin studies revealed that at a cut off point of 50 µg/g 
(ie, above the normal range) calprotectin has a sensitiv-
ity and specificity of 89% and 81% in discriminating 
IBD from non-IBD diagnoses.30 The same paper shows 
that at a threshold of 100 µg/g (twice upper limit of 
normal) the sensitivity and specificity improve to 98% 
and 91%, respectively. A normal biomarker result in a 
patient with active symptoms is therefore very reassur-
ing and may be enough, in the correct context where 
the clinical risk of malignancy is low, to avoid further 
colonic investigation such as radiology or colonoscopy 
and allow a positive diagnosis of functional diarrhoea 
or IBS at first clinic visit.
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A recent meta-analysis from the Netherlands has con-
cluded an impressive potential reduction in the number 
of adults requiring colonoscopy by 67% and children 
by 35% through incorporating faecal calprotectin as 
a screening test for IBD.29 However the authors do 
caution that false negative results may lead to delayed 
diagnosis in 6% of adults and 8% of children.
Faecal biomarkers also have a role in assessing the 
small intestine, often beyond the reach of conven-
tional colonoscopy as demonstrated by a UK study that 
compared calprotectin to small bowel barium follow 
through.31 Nine of 25 patients with active Crohn’s dis-
ease had abnormal radiology. In all cases calprotectin 
was raised to >60 µg/g and the authors found that a 
calprotectin <60 µg/g had a 100% negative predictive 
value for an abnormal follow through result.
Faecal lactoferrin has also been compared with fae-
cal occult blood (FOB) testing for its predictive capa-
bilities in colorectal disease. A study of 351 patients 
attending for colonoscopy who gave a stool sample 
the preceding day found FOB and lactoferrin to have 
equal specificity (88.7%) in predicting organic pathol-
ogy including IBD, colorectal cancer and polyps.32
Longitudinal monitoring of IBD
For many years treatment success and trial efficacy in 
IBD has been defined by symptom resolution. When 
the CDAI was created almost 35 years ago, it was 
developed as a method of standardising entry into 
clinical trials but not as a method of individually moni-
toring patients.33 Although CDAI and UCAI may give 
an indirect suggestion of disease activity, they are not 
direct measures of mucosal inflammation and may be 
raised by non-inflammatory symptoms. Faecal biomar-
kers may challenge the supremacy of the CDAI and 
UCAI by providing a real time indication of disease 
activity that can be measured longitudinally and that 
correlates well with clinical, endoscopic and histologi-
cal activity in IBD.
It has previously been shown that normalisation 
of calprotectin is a surrogate marker of endoscopic 
mucosal healing in patients being treated for active 
IBD.5 Mucosal healing may be the optimal outcome of 
therapy in IBD, as it is associated with more sustained 
clinical remission and a reduced need for surgery.34 A 
raised or normal biomarker result in a patient with 
IBD can therefore be a very useful decision making aid 
when investigating changing symptoms that may be 
due to an inflammatory flare of the disease, co-existing 
IBS, non-inflammatory complications (eg, adhesions), 
or post operative changes such as bile acid malabsorp-
tion or short bowel syndrome.14
A recent study has looked at whether calprotectin 
can give insight into the symptoms of patients previ-
ously labelled as having concomitant IBS and IBD. The 
study found that 59.7% of patients with Crohn’s dis-
ease and 38.6% of patients with UC in clinical remis-
sion fulfilled the Rome II criteria for IBS.35 However, 
they found that in these groups, calprotectin levels 
were significantly elevated above normal and were 
higher than in those patients without IBS symptoms. 
This suggests that some patients may be mislabelled as 
having concomitant IBS when in fact they have uncon-
trolled IBD driving their symptoms. Consequently, cal-
protectin may be able to help identify those patients 
who may benefit from disease-modifying treatment 
rather than symptomatic treatment.
Many studies have shown both biomarkers to cor-
relate strongly with invasive methods of determining 
extent and severity of mucosal inflammation such as 
99-technetium white cell scanning and colonoscopy 
in both adults and children.36 37 Equally, overall the 
biomarkers have been found to correlate well with 
clinical disease activity.16 17 19 21 However there have 
been some exceptions demonstrating poor clinical 
correlation between CDAI and faecal biomarkers, but 
good correlation between endoscopic activity and fae-
cal biomarkers.38 Rather than this representing a flaw 
in the use of biomarkers, it further highlights the prob-
lem that clinical indices of disease activity can underes-
timate the level of mucosal inflammation.
Furthermore it has been shown that calprotec-
tin correlates better with histological disease activity 
than macroscopic inflammation judged by clinicians 
at endoscopy. Again this suggests that biomarkers can 
provide accurate non-invasive information regarding 
mucosal disease activity, without necessarily the need 
for colonoscopy.36
There are limited but very encouraging studies regard-
ing faecal biomarkers to assess the response to inflixi-
mab treatment in Crohn’s disease. Faecal lactoferrin 
has been measured in a paediatric population of five 
patients with severe Crohn’s disease as determined by 
the paediatric CDAI receiving infliximab induction.39 
Within 7–10 days the concentration of faecal lactofer-
rin reduced by 93.43±4.49% towards baseline, prob-
ably reflecting mucosal healing although endoscopy 
was not performed to correlate this. A further study 
endoscopically assessing response to treatment found 
that in those who achieved endoscopic remission after 
infusion, faecal biomarkers fell from a pre-infusion 
mean of 1891 µg/g calprotectin (range 813–2434) and 
92.4 µg/g lactoferrin (range 35.5–235.6), to a nor-
mal post-infusion mean of 27 µg/g calprotectin (range 
13–130) and 1.9 µg/g lactoferrin (range 0.0–2.1), 
therefore providing a surrogate marker of response 
and also mucosal healing.40
Faecal biomarkers may also be of clinical use to 
monitor Crohn’s disease following intestinal resec-
tion. In this setting inflammatory relapse is common, 
but can be difficult to identify clinically as symptoms 
may be due to IBS, bile salt malabsorption or altered 
gut anatomy, often necessitating radiological or endo-
scopic investigation. A UK study has shown in the 
normal postoperative period both lactoferrin and 
calprotectin normalise within 2 months. Therefore a 
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but also to exclude other causes of raised biomarkers 
including malignancy, polyps, viral or bacterial gastro-
enteritis, NSAID enteropathy, untreated coeliac disease 
or gastro-oesophageal reflux disease.27 Therefore the 
use of faecal biomarkers should be restricted to situ-
ations where the result along with clinical judgement 
informs a decision about treatment, allows avoidance 
of invasive tests, or where invasive tests have not pro-
vided a satisfactory conclusion—for example, a nor-
mal colonoscopy but clinical suspicion of small bowel 
inflammation.
It is also necessary to appreciate that inflamma-
tion is only one component of IBD and it is only with 
regard to this that faecal biomarkers are of clinical 
use. Symptomatic patients with IBD who have normal 
biomarkers should not simply be labelled as having 
IBS without further consideration. Patients may have 
symptoms due to non-inflammatory mechanical dis-
ease such as bile salt malabsorption, fibrotic strictures 
or adhesions and these are likely to be best treated by 
identifying the correct problem and giving specific 
treatment.
Furthermore, symptoms remain the most powerful 
mediators of patient behaviour and decision making. 
As such the greatest challenge to incorporating faecal 
biomarkers into management pathways may be when 
there is disparity between how a patient feels and what 
faecal biomarkers inform us regarding their current 
inflammatory activity. For instance, it may be very dif-
ficult trying to encourage a patient with no symptoms 
and a positive faecal biomarker that they should begin 
powerful immunosuppressant treatment that poses 
risk of side effect.
Conclusions and the future for faecal biomarkers 
in IBD
The outlook for faecal calprotectin and lactoferrin in 
clinical practice appears promising.
Potentially in the future faecal biomarker measure-
ment will be standard prior to first gastrointestinal 
outpatient clinic visit for those with abdominal pain or 
diarrhoea. This may allow faster triage and assessment 
of patients and perhaps the avoidance of unnecessary 
investigation in those with functional diarrhoea or IBS.
As surrogate markers of mucosal healing in IBD, 
calprotectin and lactoferrin may allow objective map-
ping of an individual patient response to treatment and 
quantify the likelihood of future relapse. If these tests 
can be used to demonstrate an adequate response to 
biological therapy, they may aid decisions regarding 
dose escalation, shortening of dosage interval, switch-
ing to an alternative agent or ultimately withdrawal 
of unnecessary immunosuppression for those in sus-
tained deep remission. Equally future trials may tell us 
whether consistent suppression or elevation of calpro-
tectin and lactoferrin convey prognostic significance in 
terms of hospitalisation, the need for surgery and an 
effect on quality of life.
single biomarker measurement in patients with symp-
toms after this time point may aid decision making 
about further investigation for surgical complications 
or disease recurrence if the biomarker is positive, or a 
trial of conservative treatment such as loperamide or 
cholestyramine if the biomarker is within the normal 
range.14
Further support for the use of biomarkers postoper-
atively can be derived from an Italian paper of biomar-
ker correlation to disease activity.23 In this study 12 
patients had undergone surgery for Crohn’s disease 
and eight had disease recurrence involving the anasto-
mosis, all of whom had a positive calprotectin. Of the 
four with no recurrence at the anastomosis none had 
an elevated calprotectin. Similarly a positive lactofer-
rin in a symptomatic patient following ileal pouch-anal 
anastomosis surgery has been demonstrated to give a 
sensitivity of 100% and specificity of 85% in distin-
guishing between active Crohn’s disease, pouchitis 
and cuffitis, versus irritable pouch syndrome, in which 
inflammation is not driving symptoms.8
Predicting the clinical course of IBD
An important question is whether single or sequen-
tial measurement of faecal biomarkers can predict the 
future course of IBD? If so, their use in clinical practice 
is potentially vast, allowing early counselling regarding 
the need for institution of immunosuppressive or bio-
logical drugs, or surgery. Equally biomarker measure-
ment may allow discontinuation of unnecessary drugs 
in those at high likelihood of staying in remission long 
term.
A UK study monitored 43 patients with Crohn’s dis-
ease and 37 patients with UC whom had been in clini-
cal remission for between 1 and 4 months.41 An index 
calprotectin >50 mg/l (an older unit measurement of 
calprotectin that equates to >250 µg/g) predicted clin-
ical relapse over the next 12 months with a sensitivity 
of 90% and a specificity of 83%.
Similarly another study followed up 38 patients with 
Crohn’s disease and 41 patients with UC in clinical 
remission, again for 1 year.42 An index calprotectin of 
>150 µg/g was a poor indicator of relapse according 
to CDAI in Crohn’s disease, conferring only a twofold 
risk of relapse, with a sensitivity of 87% but a specifi-
city of only 47%. However, in UC the same calprotec-
tin threshold gave rise to an impressive 14-fold risk 
of relapse, with a sensitivity of 89% and a specificity 
of 82%.
What cautions and limitations are there of using 
faecal biomarkers?
It is important to remember that despite all of this 
promising data, faecal biomarker quantification as a 
screening test for IBD cannot fully replace conven-
tional endoscopy and radiology. IBD remains a his-
tological diagnosis requiring intestinal biopsies, so a 
positive calprotectin or lactoferrin will require further 
tests not only to confirm or refute a diagnosis of IBD, 
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In summary, faecal biomarkers will never fully 
replace colonoscopy and radiology which are neces-
sary to obtain tissue samples and investigate the com-
plications of IBD. However, in a society where patient 
satisfaction, risk minimisation, cost reduction and 
hospitalisation avoidance are a priority, these non-
 invasive, inexpensive, reproducible and clinically sig-
nificant measurements are likely to have a greater role 
in our future diagnostic and therapeutic pathways.
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